Decreased serum levels of adiponectin in adult attention deficit hyperactivity disorder

Psychiatry Research

Volumn 216, Issue 1, 2014, Pages 123-130

  Mavroconstanti, Thegna ^a,b   Halmøy, Anne ^a,b   Haavik, Jan ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

ADHD; Biomarker; CDH13; Psychiatry; Serum adiponectin; T cadherin

Indexed keywords

ADIPONECTIN; CADHERIN; BIOLOGICAL MARKER; GENETIC MARKER; H-CADHERIN;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CDH13 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SELF REPORT; SYMPTOMATOLOGY; AGED; BLOOD; CASE CONTROL STUDY; GENETIC MARKER; GENETICS; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; CADHERINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION, MISSENSE;

EID: 84895866856     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.01.025     Document Type: Article

References (73)

1. Agranat-Meged A.N., Deitcher C., Goldzweig G., Leibenson L., Stein M., Galili-Weisstub E. Childhood obesity and attention deficit/hyperactivity disorder: a newly described comorbidity in obese hospitalized children. International Journal of Eating Disorders 2005, 37:357-359.
2. Akiskal H.S., Mendlowicz M.V., Jean-Louis G., Rapaport M.H., Kelsoe J.R., Gillin J.C., Smith T.L. TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament. Journal of Affective Disorders 2005, 85:45-52.
3. Albayrak O., Putter C., Volckmar A.L., Cichon S., Hoffmann P., Nothen M.M., Jockel K.H., Schreiber S., Wichmann H.E., Faraone S.V., Neale B.M., Herpertz-Dahlmann B., Lehmkuhl G., Sinzig J., Renner T.J., Romanos M., Warnke A., Lesch K.P., Reif A., Schimmelmann B.G., Scherag A., Hebebrand J., Hinney A. Common obesity risk alleles in childhood attention-deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2013, 162B:295-305.
4. Amitani H., Asakawa A., Ogiso K., Nakahara T., Ushikai M., Haruta I., Koyama K., Amitani M., Cheng K.C., Inui A. The role of adiponectin multimers in anorexia nervosa. Nutrition 2013, 29:203-206.
5. Ari M., Ozturk O.H., Bez Y., Arica S., Can Y., Erduran D. Serum adiponectin and resistin levels in patients with obsessive compulsive disorder. Journal of Affective Disorders 2012, 136:979-982.
6. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999, 257:79-83.
7. Atmaca M., Ustundag B., Metin K., Topuz M. Low plasma adiponectin levels in obsessive-compulsive disorder. Journal of Affective Disorders 2009, 117:205-207.
8. Bai Y.M., Su T.P., Chen M.H., Chen T.J., Chang W.H. Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. Journal of Affective Disorders 2013, 150:57-62.
9. Banerjee T.D., Middleton F., Faraone S.V. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatrica 2007, 96:1269-1274.
10. Barbosa I.G., Rocha N.P., de Miranda A.S., Magalhaes P.V., Huguet R.B., de Souza L.P., Kapczinski F., Teixeira A.L Increased levels of adipokines in bipolar disorder. Journal of Psychiatric Research 2012, 46:389-393.
11. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biological Psychiatry 2005, 57:1215-1220.
12. Choudhry Z., Sengupta S.M., Grizenko N., Thakur G.A., Fortier M.E., Schmitz N., Joober R. Association between obesity-related gene FTO and ADHD. Obesity 2013, 21:E738-E744.
13. Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T.M. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2006, 51:382-386.
14. Denzel M.S., Scimia M.C., Zumstein P.M., Walsh K., Ruiz-Lozano P., Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. The Journal of Clinical Investigation 2010, 120:4342-4352.
15. Faraone S.V., Doyle A.E. The nature and heritability of attention-deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America 2001, 10:299-316. (viii-ix).
16. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., Sklar P Molecular genetics of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005, 57:1313-1323.
17. Faraone S.V., Sergeant J., Gillberg C., Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2:104-113.
18. Fayyad J., De Graaf R., Kessler R., Alonso J., Angermeyer M., Demyttenaere K., De Girolamo G., Haro J.M., Karam E.G., Lara C., Lepine J.P., Ormel J., Posada-Villa J., Zaslavsky A.M., Jin R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry: The Journal of Mental Science 2007, 190:402-409.
19. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. Journal of Pharmaceutical and Biomedical Analysis 2000, 21:1249-1273.
20. Fleming J.P., Levy L.D., Levitan R.D. Symptoms of attention deficit hyperactivity disorder in severely obese women. Eating and Weight Disorders: EWD 2005, 10:e10-13.
21. Franke B., Faraone S.V., Asherson P., Buitelaar J., Bau C.H., Ramos-Quiroga J.A., Mick E., Grevet E.H., Johansson S., Haavik J., Lesch K.P., Cormand B., Reif A. The genetics of attention deficit/hyperactivity disorder in adults, a review. Molecular Psychiatry 2012, 17:960-987.
22. Fujita-Shimizu A., Suzuki K., Nakamura K., Miyachi T., Matsuzaki H., Kajizuka M., Shinmura C., Iwata Y., Suda S., Tsuchiya K.J., Matsumoto K., Sugihara G., Iwata K., Yamamoto S., Tsujii M., Sugiyama T., Takei N., Mori N. Decreased serum levels of adiponectin in subjects with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:455-458.
23. Germano E., Gagliano A., Curatolo P. Comorbidity of ADHD and dyslexia. Developmental Neuropsychology 2010, 35:475-493.
24. Halfon N., Larson K., Slusser W. Associations between obesity and comorbid mental health, developmental, and physical health conditions in a nationally representative sample of US children aged 10 to 17. Academic Pediatrics 2013, 13:6-13.
25. Halmoy A., Fasmer O.B., Gillberg C., Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. Journal of Attention Disorders 2009, 13:175-187.
26. Halmoy A., Halleland H., Dramsdahl M., Bergsholm P., Fasmer O.B., Haavik J. Bipolar symptoms in adult attention-deficit/hyperactivity disorder: a cross-sectional study of 510 clinically diagnosed patients and 417 population-based controls. The Journal of Clinical Psychiatry 2010, 71:48-57.
27. Halmoy A., Klungsoyr K., Skjaerven R., Haavik J. Pre- and perinatal risk factors in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 2012, 71:474-481.
28. Hara K., Horikoshi M., Yamauchi T., Yago H., Miyazaki O., Ebinuma H., Imai Y., Nagai R., Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29:1357-1362.
29. Hirose H., Yamamoto Y., Seino-Yoshihara Y., Kawabe H., Saito I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. Journal of Atherosclerosis and Thrombosis 2010, 17:1201-1211.
30. Hirschfeld R.M., Williams J.B., Spitzer R.L., Calabrese J.R., Flynn L., Keck P.E., Lewis L., McElroy S.L., Post R.M., Rapport D.J., Russell J.M., Sachs G.S., Zajecka J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. The American Journal of Psychiatry 2000, 157:1873-1875.
31. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10308-10313.
32. Johansson S., Halleland H., Halmoy A., Jacobsen K.K., Landaas E.T., Dramsdahl M., Fasmer O.B., Bergsholm P., Lundervold A.J., Gillberg C., Hugdahl K., Knappskog P.M., Haavik J. Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2008, 147B:1470-1475.
33. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 2005, 26:439-451.
34. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of Clinical Investigation 2006, 116:1784-1792.
35. Kessler R.C., Adler L., Ames M., Demler O., Faraone S., Hiripi E., Howes M.J., Jin R., Secnik K., Spencer T., Ustun T.B., Walters E.E. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychological Medicine 2005, 35:245-256.
36. Klassen L.J., Bilkey T.S., Katzman M.A., Chokka P. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Current Drug Abuse Reviews 2012, 5:190-198.
37. Landaas E.T., Halmoy A., Oedegaard K.J., Fasmer O.B., Haavik J. The impact of cyclothymic temperament in adult ADHD. Journal of Affective Disorders 2012, 142:241-247.
38. Langley K., Rice F., van den Bree M.B., Thapar A. Maternal smoking during pregnancy as an environmental risk factor for attention deficit hyperactivity disorder behaviour. a review. Minerva Pediatrica 2005, 57:359-371.
39. Lasky-Su J., Neale B.M., Franke B., Anney R.J., Zhou K., Maller J.B., Vasquez A.A., Chen W., Asherson P., Buitelaar J., Banaschewski T., Ebstein R., Gill M., Miranda A., Mulas F., Oades R.D., Roeyers H., Rothenberger A., Sergeant J., Sonuga-Barke E., Steinhausen H.C., Taylor E., Daly M., Laird N., Lange C., Faraone S.V. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 2008, 147B:1345-1354.
40. Lehto S.M., Elomaa A.P., Niskanen L., Herzig K.H., Tolmunen T., Viinamaki H., Koivumaa-Honkanen H., Huotari A., Honkalampi K., Valkonen-Korhonen M., Sinikallio S., Ruotsalainen H., Hintikka J. Serum adipokine levels in adults with a history of childhood maltreatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012, 37:217-221.
41. Lehto S.M., Huotari A., Niskanen L., Tolmunen T., Koivumaa-Honkanen H., Honkalampi K., Ruotsalainen H., Herzig K.H., Viinamaki H., Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatrica Scandinavica 2010, 121:209-215.
42. Leo R., Di Lorenzo G., Tesauro M., Cola C., Fortuna E., Zanasi M., Troisi A., Siracusano A., Lauro R., Romeo F. Decreased plasma adiponectin concentration in major depression. Neuroscience Letters 2006, 407:211-213.
43. Lesch K.P., Timmesfeld N., Renner T.J., Halperin R., Roser C., Nguyen T.T., Craig D.W., Romanos J., Heine M., Meyer J., Freitag C., Warnke A., Romanos M., Schafer H., Walitza S., Reif A., Stephan D.A., Jacob C. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. Journal of Neural Transmission 2008, 115:1573-1585.
44. Liu J., Guo M., Zhang D., Cheng S.Y., Liu M., Ding J., Scherer P.E., Liu F., Lu X.Y. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:12248-12253.
45. Mavroconstanti T., Johansson S., Winge I., Knappskog P.M., Haavik J. Functional properties of rare missense variants of human CDH13 found in Adult Attention Deficit/Hyperactivity Disorder (ADHD) patients. PloS ONE 2013, 8:e71445.
46. Michielsen M., Comijs H.C., Semeijn E.J., Beekman A.T., Deeg D.J., Sandra Kooij J.J. The comorbidity of anxiety and depressive symptoms in older adults with attention-deficit/hyperactivity disorder: a longitudinal study. Journal of Affective Disorders 2013, 148:220-227.
47. Morisaki H., Yamanaka I., Iwai N., Miyamoto Y., Kokubo Y., Okamura T., Okayama A., Morisaki T. CDH13 gene coding T-cadherin influences variations in plasma adiponectin levels in the Japanese population. Human Mutation 2012, 33:402-410.
48. Narita K., Murata T., Hamada T., Takahashi T., Kosaka H., Sudo S., Mizukami K., Yoshida H., Wada Y. Adiponectin multimer distribution, not absolute amount of plasma, correlates with depression severity in healthy elderly subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:124-127.
49. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51:2734-2741.
50. Oh D.K., Ciaraldi T., Henry R.R. Adiponectin in health and disease. Diabetes, Obesity and Metabolism 2007, 9:282-289.
51. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A The worldwide prevalence of ADHD: a systematic review and metaregression analysis. The American Journal of Psychiatry 2007, 164:942-948.
52. Rivero O., Sich S., Popp S., Schmitt A., Franke B., Lesch K.P. Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2012, 23:492-507.
53. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., Nagai M., Matsuzawa Y., Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal: Official Journal of the Japanese Circulation Society 2004, 68:975-981.
54. Scassellati C., Bonvicini C., Faraone S.V., Gennarelli M. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry 2012, 51:1003-1019.e1020.
55. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. The Journal of Biological Chemistry 1995, 270:26746-26749.
56. Schulz C., Paulus K., Lehnert H. Adipocyte-brain: crosstalk. Results and Problems in Cell Differentiation 2010, 52:189-201.
57. Seino Y., Hirose H., Saito I., Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism: Clinical and Experimental 2007, 56:1493-1499.
58. Shehzad A., Iqbal W., Shehzad O., Lee Y.S. Adiponectin: regulation of its production and its role in human diseases. Hormones 2012, 11:8-20.
59. Simon V., Czobor P., Balint S., Meszaros A., Bitter I Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science 2009, 194:204-211.
60. Smoller J.W., Craddock N., Kendler K., Lee P.H., Neale B.M., Nurnberger J.I., Ripke S., Santangelo S., Sullivan P.F. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379.
61. Stanley S.H., Laugharne J.D. Obesity, cardiovascular disease and type 2 diabetes in people with a mental illness: a need for primary health care. Australian Journal of Primary Health 2012, 18:258-264.
62. Stanley S.H., Laugharne J.D., Addis S., Sherwood D. Assessing overweight and obesity across mental disorders: personality disorders at high risk. Social Psychiatry and Psychiatric Epidemiology 2013, 48:487-492.
63. Sukumaran S., Dubois D.C., Jusko W.J., Almon R.R. Glucocorticoid effects on adiponectin expression. Vitamins and Hormones 2012, 90:163-186.
64. Teixeira A.L., Diniz B.S., Campos A.C., Miranda A.S., Rocha N.P., Talib L.L., Gattaz W.F., Forlenza O.V. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer[U+05F3]s disease. Neuromolecular Medicine 2012.
65. Thundyil J., Pavlovski D., Sobey C.G., Arumugam T.V. Adiponectin receptor signalling in the brain. British Journal of Pharmacology 2012, 165:313-327.
66. Tsao T.S., Tomas E., Murrey H.E., Hug C., Lee D.H., Ruderman N.B., Heuser J.E., Lodish H.F. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. The Journal of Biological Chemistry 2003, 278:50810-50817.
67. Unsal C., Hariri A.G., Yanartas O., Sevinc E., Atmaca M., Bilici M. Low plasma adiponectin levels in panic disorder. Journal of Affective Disorders 2012, 139:302-305.
68. Ward M.F., Wender P.H., Reimherr F.W. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. The American Journal of Psychiatry 1993, 150:885-890.
69. Wolf A.M., Wolf D., Rumpold H., Enrich B., Tilg H Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochemical and Biophysical Research Communications 2004, 323:630-635.
70. Wu Y., Li Y., Lange E.M., Croteau-Chonka D.C., Kuzawa C.W., McDade T.W., Qin L., Curocichin G., Borja J.B., Lange L.A., Adair L.S., Mohlke K.L. Genome-wide association study for adiponectin levels in Filipino women identifies CDH13 and a novel uncommon haplotype at KNG1-ADIPOQ. Human Molecular Genetics 2010, 19:4955-4964.
71. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
72. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001, 7:941-946.
73. Yatagai T., Nagasaka S., Taniguchi A., Fukushima M., Nakamura T., Kuroe A., Nakai Y., Ishibashi S. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003, 52:1274-1278.